Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well selumetinib works in treating patients with biliary
cancer that cannot be removed by surgery. Selumetinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.